Jacobs Levy Equity Management Inc. increased its position in Humana Inc. (NYSE:HUM - Free Report) by 0.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 589,287 shares of the insurance provider's stock after buying an additional 1,615 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.49% of Humana worth $149,508,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently bought and sold shares of the company. Humankind Investments LLC lifted its holdings in shares of Humana by 32.6% in the 4th quarter. Humankind Investments LLC now owns 1,612 shares of the insurance provider's stock worth $409,000 after acquiring an additional 396 shares during the last quarter. Gotham Asset Management LLC raised its position in Humana by 38.9% in the 4th quarter. Gotham Asset Management LLC now owns 32,593 shares of the insurance provider's stock worth $8,269,000 after purchasing an additional 9,132 shares during the period. Ethic Inc. lifted its stake in Humana by 7.7% in the fourth quarter. Ethic Inc. now owns 8,641 shares of the insurance provider's stock worth $2,192,000 after purchasing an additional 619 shares during the last quarter. Fred Alger Management LLC purchased a new stake in Humana during the fourth quarter valued at about $451,000. Finally, Family Management Corp bought a new position in shares of Humana during the fourth quarter valued at about $3,134,000. Institutional investors own 92.38% of the company's stock.
Humana Stock Up 4.4%
Shares of NYSE:HUM traded up $9.95 during trading on Friday, hitting $237.42. The stock had a trading volume of 2,542,509 shares, compared to its average volume of 1,767,488. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 12 month low of $212.45 and a 12 month high of $406.46. The company has a market capitalization of $28.65 billion, a PE ratio of 23.86, a PEG ratio of 2.05 and a beta of 0.49. The firm's fifty day moving average is $263.20 and its 200 day moving average is $269.61.
Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.07 by $1.51. The business had revenue of $32.11 billion during the quarter, compared to the consensus estimate of $32 billion. Humana had a return on equity of 11.70% and a net margin of 1.02%. The firm's quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $7.23 earnings per share. Analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.
Humana Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.49%. The ex-dividend date of this dividend is Friday, June 27th. Humana's dividend payout ratio is 25.04%.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on HUM shares. Barclays boosted their target price on Humana from $270.00 to $322.00 and gave the company an "equal weight" rating in a research note on Friday, April 11th. Mizuho boosted their price objective on Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research report on Wednesday, April 9th. Raymond James upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 target price on the stock in a report on Thursday, May 1st. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $290.00 target price on shares of Humana in a research note on Thursday, May 1st. Finally, Truist Financial lowered their price target on shares of Humana from $325.00 to $305.00 and set a "hold" rating for the company in a report on Monday. Seventeen analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $286.81.
Get Our Latest Stock Report on HUM
About Humana
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Recommended Stories
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
